# Carotuximab

Source: https://onco.cc/drugs/carotuximab/  
OnCo record `carotuximab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Carotuximab was an antibody against endoglin, a protein on growing blood vessels and on angiosarcoma cells. Added to pazopanib in the phase 3 TAPPAS trial it did not help, and the trial was stopped in 2019.

## Summary

Carotuximab (TRC105) was Tracon Pharmaceuticals' antibody against endoglin, a marker of angiogenic endothelium and of angiosarcoma, a cancer that arises from blood vessel lining. Endoglin signalling was thought to be one way tumours escape VEGF blockade, so the antibody was combined with VEGFR inhibitors. Early-phase results in angiosarcoma with pazopanib were encouraging.

The randomised phase 3 TAPPAS trial of pazopanib with or without carotuximab in advanced angiosarcoma was stopped in 2019 after an interim analysis showed no improvement in progression-free survival, and the programme ended. The angiosarcoma page lists it with bevacizumab added to paclitaxel (ANGIOTAX-PLUS) among the antiangiogenic additions that failed.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-17
- Also known as: TRC105
- Tags: subtype-drugs-wave
- Code: TRC105
- Modality: Chimeric anti-endoglin (CD105) monoclonal antibody
- Mechanism: Binds endoglin (CD105), a TGF-beta co-receptor highly expressed on proliferating tumour endothelium and on angiosarcoma cells, to block a vessel-growth pathway that escapes VEGF inhibition.

## Connected records

- drugs: [Pazopanib](https://onco.cc/drugs/pazopanib/)
- cancers: [Angiosarcoma](https://onco.cc/cancers/angiosarcoma/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- companies: [Tracon Pharmaceuticals](https://onco.cc/companies/tracon/)
- trials: [TAPPAS](https://onco.cc/trials/tappas/)

---
JSON: https://onco.cc/api/v1/entities/carotuximab.json